Artelo Biosciences Inc at SRAX Sequire Biotechnology Conference (Virtual) Transcript
Hi, and welcome to the Sequire virtual biotech conference. I'm told that this is the inaugural conference, and it's great to have Artelo Biosciences joining you today. I'm Greg Gorgas, the founding CEO at Artelo.
I will be making some forward-looking statements today. We would ask all investors to please go to our website at artelobio.com, where all of our filings and disclosures are linked, and you can review more about the risks and opportunities of an investment in Artelo Biosciences.
Artelo is a clinical-stage biopharmaceutical company. We're developing a portfolio of lipid signaling modification candidates, and we're focused on people living with cancer and other serious diseases. I'd like to communicate and speak with you today about five main areas.
One, is that we have a novel drug pipeline, not just a single asset. We have near-term milestones over the next month, two months, throughout this year, and into next year, which should attract investments to Artelo. All of our programs are targeting billion-dollar
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |